Why It's Critical To Modernize GI Studies

By Dr. Charles Baum, Curebase Principal Investigator and former VP of US and EU Medical Affairs at Takeda Pharmaceuticals

In the year 2022, there have been numerous advancements in modernizing GI studies but it doesn't stop there. As new technology develops and virtual care trends become concrete, there is a growing need for innovative solutions that can accelerate and reimagine study designs. My work with Curebase has given me unique insights into where the future of GI studies are headed and how the Curebase trial execution model plays a role. 

The future of GI studies lies within the adoption of a comprehensive technology-driven solution that is flexible and amenable to the needs of the study and patients while offering innovative features to revolutionize how GI studies are designed and managed. Curebase has reshaped clinical trials and continues to pioneer new ways of conducting GI studies that aligns with where industries are headed and expand access to more patients suffering from GI conditions.